I find it incredible that we are below the SP (without a great deal of dilution in between) that we were post results of the P2 pediatric trial.
Think of the progress (without any regress) since then. The Lanstead funding, FDA approval, under favourable conditions, for the P3 and now a deal to fund that trial, with significant upside if successful plus funds to pursue 2591 development.
Crazy.
- Forums
- ASX - By Stock
- NEU
- Mass Exodus
Mass Exodus, page-50
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.60 |
Change
0.000(0.00%) |
Mkt cap ! $1.995B |
Open | High | Low | Value | Volume |
$15.64 | $15.93 | $15.44 | $6.543M | 418.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 768 | $16.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.04 | 875 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 206 | 15.590 |
8 | 575 | 15.580 |
3 | 353 | 15.570 |
3 | 355 | 15.560 |
4 | 389 | 15.550 |
Price($) | Vol. | No. |
---|---|---|
15.600 | 3243 | 8 |
15.610 | 1286 | 3 |
15.620 | 768 | 3 |
15.630 | 193 | 2 |
15.640 | 834 | 3 |
Last trade - 15.59pm 15/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online